Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant 500 mg versus anastrozole as first-line hormonal treatment for hormone receptor-positive advanced breast cancer
2005-002868-28Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Fulvestrant 500 mg with Anastrozole 1 mg (2 arms). Primary endpoint: Clinical benefit rate. Started Oct 2005; status: completed.
02
Drugs
fulvestrantanastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2005-002868-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002868-28.